%0 Journal Article
%T Initiation of Prophylactic Treatment with Subcutaneous C1-Esterase Inhibitor (C1-INH [SC]) for Prevention of Hereditary Angioedema (HAE) Attacks and Onset of Effect: Findings from the Phase III COMPACT Study
%A Bruce L. Zuraw
%A Henrike Feuersenger
%A Hilary J. Longhurst
%A Huamin Henry Li
%A Marc A. Riedl
%A Marco Cicardi
%A Timothy Craig
%J Journal of Allergy and Clinical Immunology
%D 2018
%R 10.1016/j.jaci.2017.12.147
%X Subcutaneous C1-INH (HAEGARDA£¿, CSL Behring, Marburg) at 60 IU/kg was recently approved
by the US FDA as routine prophylaxis to prevent hereditary angioedema (HAE) attacks
in adolescents and adults, based on the COMPACT study. This study demonstrated that
the median attack rate was reduced by 95% with C1-INH relative to placebo. We explored
the onset of the preventive effect of C1-INH (SC) after treatment initiation.
%U https://www.jacionline.org/article/S0091-6749(17)32047-X/abstract